Via targeting TREM2 expressed in TAMs, GB2 induces comprehensive tumor regression by administrating intravenously in mouse colon cancer models, as well as in a STINGlow mouse melanoma model, with no systemic toxicity. Here, TREM2 is linked to colonic neoplasm.